Cargando…
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
The duration of protection of the third (booster) dose of the BioNTech/Pfizer BNT162b2 mRNA Coronavirus Disease 2019 vaccine has been the subject of recent investigations, as global discussions around the necessity and effectiveness of a fourth dose are already underway. By conducting a retrospectiv...
Autores principales: | Patalon, Tal, Saciuk, Yaki, Peretz, Asaf, Perez, Galit, Lurie, Yoav, Maor, Yasmin, Gazit, Sivan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184525/ https://www.ncbi.nlm.nih.gov/pubmed/35680872 http://dx.doi.org/10.1038/s41467-022-30884-6 |
Ejemplares similares
-
Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study
por: Gazit, Sivan, et al.
Publicado: (2022) -
Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation
por: Gazit, Sivan, et al.
Publicado: (2023) -
Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents
por: Patalon, Tal, et al.
Publicado: (2023) -
Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
por: Prunas, Ottavia, et al.
Publicado: (2022) -
Mpox Patient Journey in Israel
por: Patalon, Tal, et al.
Publicado: (2023)